Idenix Pharmaceuticals, Inc.

Michel Derock

Dominique Surleraux

Francois-Rene Alexandre

Christophe Parsy

Thierry Convard

Frederic Leroy

Cyril B Dousson

David Dukhan

Jean-Laurent Paparin

Claire Pierra

Houcine Rahali

Daniel Da Costa

Guillaume Brandt

Jean-Christophe Meillon

Christophe Claude Parsy

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

Macrocyclic serine protease inhibitors

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

Growing community of inventors

Grabels, France

Michel Derock